Innoviva

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This pharmaceutical company is growing revenue and profits from drugs it doesn't market or sell.

1 Healthcare Stock That Could Fly Higher After a Strong Q4

Horace Mann Educators

Maravai LifeSciences Holdings

Meridian Bioscience

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.

Sail Through the Choppy Market With These 4 Low-Beta Stocks

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced the pricing of $225 million aggregate principal amount of the Company's 2.125% convertible senior notes due 2028 (the “Notes”). The size of the offering was increased from the previously announced offering size of $200 million. The Notes will be sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”).

Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125% Convertible Senior Notes

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced its intention to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2028 (the “Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). The Company also intends to grant the initial purchasers of the Notes an option to purc

Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Innoviva (INVA) Run Higher on Rising Earnings Estimates?

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the fourth quarter and the year ended December 31, 2021. Gross royalty revenues of $111.1 million from Glaxo Group Limited (“GSK”) for the fourth quarter of 2021 included royalties of $57.7 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $10.8 million from global net sales of ANORO® ELLIPTA® and royalties of $42.6 million from global net sa

Innoviva Reports Fourth Quarter 2021 Financial Results

Armata Pharmaceuticals Inc

MARINA DEL REY, Calif., Feb. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrants to Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder.

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development

BrightSphere Investment Group

Alphabet

Microsoft

NIKE

NVIDIA

Aaron's

Buckle

After this past year, it's going to be hard to find stocks to buy to make you a millionaire in 2022. Here's 10 that might do the trick.

10 Stocks to Buy That Could Make You a Millionaire in 2022

AbbVie

Catalyst Pharmaceuticals

Horizon Pharma

Eli Lilly

Pfizer

Zoetis

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appeared first on InvestorPlace.

7 of the Top-Rated Pharmaceutical Stocks for Q1

BURLINGAME, Calif--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the third quarter ended September 30, 2021. Gross royalty revenues of $101.3 million from Glaxo Group Limited (“GSK”) for the third quarter of 2021 included royalties of $54.1 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $11.6 million from global net sales of ANORO® ELLIPTA® and royalties of $35.6 million from global net sales of TRELEGY®

Innoviva Reports Third Quarter 2021 Financial Results

Clearside Biomedical

Mannatech

Oramed Pharmaceuticals

United Therapeutics

Veru

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first on InvestorPlace.

7 Top-Rated Pharmaceutical Stocks To Invest in for October

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the second quarter ended June 30, 2021. Gross royalty revenues of $104.3 million from Glaxo Group Limited (“GSK”) for the second quarter of 2021 included royalties of $65.9 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $12.0 million from global net sales of ANORO® ELLIPTA® and royalties of $26.4 million from global net sales of TRELEGY® E

Innoviva Reports Second Quarter 2021 Financial Results

Biogen

SAGE Therapeutics

SIGA Technologies

Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.

4 Undervalued Biotech Stocks That Belong On Every Investor's Buy List

GlaxoSmithKline

GlaxoSmithKline plc (NYSE: GSK) has agreed to sell 32 million shares in Innoviva Inc (NASDAQ: INVA) back to the royalty management company, raising $392 million, at a 3% discount or $12.25 per share. Innoviva, a royalty management company that collaborates with GSK on respiratory treatments, including Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta, has counted GSK among its investors for years.

GSK Exits Respiratory Partner Innoviva In $392M Deal

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today announced the execution of definitive agreement to purchase of GSK's equity stake in Innoviva, constituting approximately 32 million shares, or 32% of the outstanding common stock, at $12.25 per share, representing a 3% discount to the 5-day volume weighted average price of the Company's common stock, for a total purchase price of $392 million. Pavel Raifeld, Chief Executive Officer of Innovi

Innoviva Announces Strategic Repurchase of GSK's Equity Stake

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ:INVA) (“Innoviva” and “the Company”) today reported financial results for the first quarter ended March 31, 2021. Gross royalty revenues of $89.0 million from Glaxo Group Limited (“GSK”) for the first quarter of 2021 included royalties of $56.4 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $10.5 million from global net sales of ANORO® ELLIPTA® and royalties of $22.1 million from global net sales of TRELEGY® ELLI

Innoviva Reports First Quarter 2021 Financial Results

Bio-Rad Laboratories

Stocks to consider using Benjamin Graham's lost formula amid lingering pandemic fears

3 Health Care Stocks Trading Below Graham's Valuation

Coupang

Keurig Dr Pepper Inc

Biohaven Pharmaceutical Hld

GoHealth, Inc.

JOANN

Merchants Bancorp

PennyMac Financial Services

Prometheus Biosciences

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.

The Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More

Atlas Air Worldwide

Cabot

Acushnet Hlds

Quaker Chemical

The Dow slipped 0.1%, the S&P 500 rose 0.1%, and the Nasdaq climbed 0.6%. In the meantime, Q.ai's Artificial Intelligence has brought out today's top buys.

Top Stocks To Buy Today As Markets Anxiously Anticipate Fed Meeting

Innoviva (INVA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Innoviva

I don't think this is a "buy and forget" stock by any stretch of the imagination, but if you get the timing right, it'll be a very profitable trade.

Buying Back In To Innoviva

Shares of Innoviva (NASDAQ:INVA) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 14.29% over the past year to $0.48, which beat the estimate of $0.40.

Innoviva: Q4 Earnings Insights

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2020. Gross royalty revenues of $93.9 million from Glaxo Group Limited (“GSK”) for the fourth quarter of 2020 included royalties of $55.9 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $13.1 million from global net sales of ANORO® ELLIPTA® and royalties of $24.9 million from global net sales of TRELEGY® ELLIPTA®.[1] In

Innoviva Reports Fourth Quarter 2020 Financial Results

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.

What's in Store for Innoviva (INVA) This Earnings Season?

In the latest trading session, Innoviva (INVA) closed at $12.51, marking a +1.71% move from the previous day.

Innoviva (INVA) Gains As Market Dips: What You Should Know

News for Innoviva Stock (INVA)